Skip to content

Author

N. Singla

We have 9 of 558 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer

This economic evaluation assesses the health economic value, for a US Medicare payer, of adopting perioperative enfortumab vedotin plus pembrolizumab for treatment of cisplatin-ineligible patients with muscle-invasive bladder cancer.

Z. Su, Tyler S. Garman, Carlos A. Rivera López et al. · 0 citations
Oct 2026

Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab.

PURPOSE Enfortumab vedotin and pembrolizumab (EVP) is the standard first-line treatment for locally advanced and metastatic urothelial cancer (la/mUC) although response biomarkers remain an unmet need. Tumor-informed circulating tumor DNA (ctDNA) has proven to be useful as a marker of response in a variety of cancers....

Vivek Nimgaonkar, A. Arbuiso, Evangelia-Eirini N. Vlachou et al. · 0 citations
Open access Oct 2026

Epithelial to mesenchymal transition and M2 macrophages drive aggressiveness in murine and human sarcomatoid urothelial carcinoma

Patients with majority variant subtype histology including sarcomatoid urothelial carcinoma (SUC) have poor outcomes and limited treatment options, and there are few preclinical resources to investigate rare histologic subtypes. We developed three novel variant subtype histology bladder cancer (BC) cell lines by findin...

Yujiro Hayashi, Roy Elias, Eugene F. Douglass et al. · 0 citations
Open access Sep 2026

36 Clear Cell Renal Cell Carcinoma Consensus Transcriptomic Programs Reveal Converging Trajectories Towards Aggressive Disease

A multi-cohort, multi-rank consensus workflow that identifies recurrent non-negative matrix factorization (NMF) factors, termed consensus transcriptomic programs (CTPs), across independent ccRCC bulk RNA-seq datasets and across a range of factorization dimensionalities is developed.

Roy Elias, Vivek Nimgaonkar, B. Xie et al. · 0 citations
Open access Sep 2026

Is a Few Too Many? Alcohol Consumption and Prostate Cancer Upgrading During Active Surveillance.

BACKGROUND The association between alcohol consumption and prostate cancer (PCa) outcomes remains mixed, with particularly limited data on the association between alcohol consumption and risk of upgrading among men undergoing active surveillance (AS). METHODS We analyzed men with Grade Group (GG) 1 PCa managed in a p...

Jack A. Campbell, Michelle I. Higgins, Z. Su et al. · 0 citations
Sep 2026

Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma.

ML models using preoperative variables achieved moderate discrimination for predicting adverse pathological features in UTUC and external validation and prospective assessment of clinical utility are necessary before informing preoperative patient selection.

Philipp Korn, Maximilian Pallauf, S. Lokeshwar et al. · 0 citations
Review Jul 2026

Spatial distribution and prognostic significance of hemorrhagic imaging features in brain metastases from metastatic renal cell carcinoma

In this surgically managed RCC BM cohort, brain metastases from mRCC demonstrate nonrandom spatial distribution, with overrepresentation in posterior circulation and posterior cerebral artery territories.

Jia-Zhang Xing, Ardit Feinaj, Zsombor Ritter et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.